Tesofensine Results: How Fast Does It Work?
Tesofensine generated significant excitement when its Phase 2 trial results were published — showing nearly six times the weight loss of placebo over 24 weeks. Unlike GLP-1 agonists, it works through a completely different mechanism: blocking the reuptake of serotonin, dopamine, and noradrenaline simultaneously. Here's what the data actually shows, how quickly effects appear, and why this compound never made it to Phase 3.
Research use only. Tesofensine is not FDA-approved for any indication. It exists exclusively as a research compound. This article is for educational purposes.
Tesofensine originated as a Parkinson's disease compound — researchers noticed significant unintended weight loss in trial participants and pivoted development toward obesity. Its mechanism is unlike any GLP-1 agent or GH peptide: it blocks the reuptake transporters for all three monoamine neurotransmitters.
Serotonin reuptake inhibition
Increases serotonin availability at neural synapses — contributes to satiety and mood improvement during caloric restriction. Similar mechanism to classic anti-obesity drugs like fenfluramine.
Dopamine reuptake inhibition
Modulates reward pathway sensitivity to food. May reduce the motivational drive toward high-calorie 'reward' foods. This is a key differentiator from GLP-1 agents.
Noradrenaline reuptake inhibition
The noradrenaline component increases sympathetic nervous system tone — raising metabolic rate slightly and contributing to the total energy expenditure increase observed in trials.
Triple monoamine reuptake
The combined triple reuptake inhibition produces an additive appetite suppression effect more powerful than any single mechanism alone, and operates through an entirely different pathway from GLP-1 or GH secretagogues.
6.5%
0.25 mg/day
11.3%
0.5 mg/day
12.8%
1.0 mg/day
2.2%
Placebo
Study design: 203 obese patients, 24 weeks, randomised double-blind placebo-controlled. The 12.8% weight loss at 1mg was compared to 2.2% in the placebo group — a net advantage of ~10.6 percentage points. At the time of publication, these were among the strongest Phase 2 obesity trial results ever reported.
Timeline of Effects
Appetite suppression onset
Noradrenaline and dopamine reuptake inhibition reduces appetite within the first week. Many users report dramatically reduced hunger and reduced food preoccupation during this phase.
Early weight loss
Caloric restriction driven by appetite suppression begins to produce measurable weight loss. Early losses are partially fluid and glycogen depletion alongside fat loss.
Accelerated fat loss phase
The Phase 2 trial ran 24 weeks. The most significant weight reduction occurred in the first 12 weeks. At 0.5mg, participants lost approximately 6.7% of body weight by week 12.
Plateau and maintenance
Weight loss slows as the body adapts. The Phase 2 trial reported 12.8% total weight loss at highest dose over 24 weeks — roughly double the rate of comparator compounds in the same study.
Despite exceptional Phase 2 results, tesofensine's development stalled. The primary concern was a cardiovascular safety signal — specifically, increased heart rate and blood pressure observed at the 1mg dose. This is mechanistically expected from a noradrenaline reuptake inhibitor: increased sympathetic tone raises resting heart rate.
In an era (2008–2012) where the FDA was tightening cardiovascular safety requirements for obesity drugs following the withdrawal of rimonabant and concerns with sibutramine, the heart rate elevation was enough to stall Phase 3 investment. The 0.5mg dose showed a better cardiovascular profile but somewhat lower weight loss.
Current status: No Phase 3 trial has been initiated in major markets. Tesofensine remains available as a research compound. Some jurisdictions (notably parts of Latin America) have seen it investigated in smaller clinical contexts. The rise of GLP-1 agents with superior safety profiles and FDA approval has further reduced commercial development incentive.
Tesofensine — Research Grade
Available from Base Peptides for research applications.
Weight Loss Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →